

EMBARGOED: Until 11:59 (Barcelona), Monday, 23 September, 2013

CONTACT: Tara Stultz, M: +1(440) 225-9595, tara.stultz@ritzcommunications.com

Researchers present findings on key proteins in newly identified target for insulin sensitizers

Data presented at 49th Annual Meeting of the European Association for the Study of Diabetes

BARCELONA, Sept. 24, 2013 – Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a new drug target through which insulin sensitizers exert their anti-diabetic effects. Insulin sensitizers treat the core problem in type 2 diabetes -- insulin resistance, which is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin. New insights into this drug target and its role in the development of potentially more useful and novel insulin sensitizers are being presented today at the 49th Annual Meeting of the European Association for the Study Diabetes.

Poster Hall
PS 049 Mitochondria, ROS and metabolism
Tuesday, 24 September 2013 – 12:30 - 13:30

Study of key proteins in the newly identified mitochondrial target of thiazolidinediones (mTOT): a new target for insulin sensitizers

Poster 701

<http://www.easdvirtualmeeting.org/contentsessions/238>

Modification of Nutrient Utilization Improves Cell Function and Insulin Sensitivity

mTOT Modulators™ appear to affect the regulation of biochemical pathways essential to maintaining the appropriate level of glucose, a major energy source for cells. Data suggest these new drugs have the potential to improve the body's sensitivity to insulin, lower the percent of calorie-storing "white" fat, increase the production of calorie-burning "brown" fat, preserve the function of pancreatic beta cells (which produce insulin), and protect neurons in the brain (which could be important in treating diseases such as [Alzheimer's](#) and [Parkinson's](#) disease).

Importance to the Future Discovery and Development of Anti-Diabetic Drugs

Clinical studies in type 2 diabetic patients of MSDC's investigational new drugs, [MSDC-0160](#) and MSDC-0602, demonstrate modulating [mTOT](#) could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases of aging, especially type 2 diabetes.

###